[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
Identifieur interne : 000019 ( Main/Exploration ); précédent : 000018; suivant : 000020[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
Auteurs : Annie Ladoux [France] ; Stéphane Azoulay [France] ; Christian Dani [France]Source :
- Medecine sciences : M/S [ 1958-5381 ]
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Betacoronavirus (enzymologie), Betacoronavirus (physiologie), Humains (MeSH), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Inhibiteurs de protéase du VIH (usage thérapeutique), Inhibiteurs de protéases (usage thérapeutique), Pandémies (prévention et contrôle), Peptide hydrolases (physiologie), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Réplication virale (MeSH).
- MESH :
- enzymologie : Betacoronavirus.
- physiologie : Betacoronavirus, Peptide hydrolases.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Inhibiteurs de protéase du VIH, Inhibiteurs de protéases.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Réplication virale.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Betacoronavirus (enzymology), Betacoronavirus (physiology), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), HIV Protease Inhibitors (therapeutic use), Humans (MeSH), Pandemics (prevention & control), Peptide Hydrolases (physiology), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Protease Inhibitors (therapeutic use), Virus Replication (MeSH).
- MESH :
- chemical , physiology : Peptide Hydrolases.
- chemical , therapeutic use : Antiviral Agents, HIV Protease Inhibitors, Protease Inhibitors.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- enzymology : Betacoronavirus.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Humans, Virus Replication.
DOI: 10.1051/medsci/2020106
PubMed: 32558640
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].</title><author><name sortKey="Ladoux, Annie" sort="Ladoux, Annie" uniqKey="Ladoux A" first="Annie" last="Ladoux">Annie Ladoux</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Azoulay, Stephane" sort="Azoulay, Stephane" uniqKey="Azoulay S" first="Stéphane" last="Azoulay">Stéphane Azoulay</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Dani, Christian" sort="Dani, Christian" uniqKey="Dani C" first="Christian" last="Dani">Christian Dani</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jun-Jul</date><idno type="RBID">pubmed:32558640</idno><idno type="pmid">32558640</idno><idno type="doi">10.1051/medsci/2020106</idno><idno type="wicri:Area/Main/Corpus">000D12</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D12</idno><idno type="wicri:Area/Main/Curation">000D12</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D12</idno><idno type="wicri:Area/Main/Exploration">000D12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].</title><author><name sortKey="Ladoux, Annie" sort="Ladoux, Annie" uniqKey="Ladoux A" first="Annie" last="Ladoux">Annie Ladoux</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Azoulay, Stephane" sort="Azoulay, Stephane" uniqKey="Azoulay S" first="Stéphane" last="Azoulay">Stéphane Azoulay</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Dani, Christian" sort="Dani, Christian" uniqKey="Dani C" first="Christian" last="Dani">Christian Dani</name><affiliation wicri:level="3"><nlm:affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author></analytic><series><title level="j">Medecine sciences : M/S</title><idno type="eISSN">1958-5381</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (enzymology)</term><term>Betacoronavirus (physiology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>Humans (MeSH)</term><term>Pandemics (prevention & control)</term><term>Peptide Hydrolases (physiology)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Protease Inhibitors (therapeutic use)</term><term>Virus Replication (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (enzymologie)</term><term>Betacoronavirus (physiologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Inhibiteurs de protéase du VIH (usage thérapeutique)</term><term>Inhibiteurs de protéases (usage thérapeutique)</term><term>Pandémies (prévention et contrôle)</term><term>Peptide hydrolases (physiologie)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Réplication virale (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Peptide Hydrolases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>HIV Protease Inhibitors</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term><term>Peptide hydrolases</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéase du VIH</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Réplication virale</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32558640</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1958-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>6-7</Issue><PubDate><MedlineDate>2020 Jun-Jul</MedlineDate></PubDate></JournalIssue><Title>Medecine sciences : M/S</Title><ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation></Journal><ArticleTitle>[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].</ArticleTitle><Pagination><MedlinePgn>555-558</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/2020106</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladoux</LastName><ForeName>Annie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3857-2621</Identifier><AffiliationInfo><Affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azoulay</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><VernacularTitle>Cibler la protéase majeure du SARS-CoV-2 pour fabriquer un médicament efficace contre ce coronavirus.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Med Sci (Paris)</MedlineTA><NlmUniqueID>8710980</NlmUniqueID><ISSNLinking>0767-0974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32558640</ArticleId><ArticleId IdType="doi">10.1051/medsci/2020106</ArticleId><ArticleId IdType="pii">msc200106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronaviridae study group of the international committee on taxonomy of V. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5 : 536–44.</Citation></Reference><Reference><Citation>Tratner I. SRAS : 1. Le virus. Med Sci (Paris) 2003 ; 19 : 885–891.</Citation></Reference><Reference><Citation>Lee EYP, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis 2020; 20 : 384–5.</Citation></Reference><Reference><Citation>Jager S, Cimermancic P, Gulbahce N, et al. Global landscape of HIV-human protein complexes. Nature 2011 ; 481 : 365–370.</Citation></Reference><Reference><Citation>James JS. Saquinavir (Invirase): first protease inhibitor approved–reimbursement, information hotline numbers. AIDS Treatment News 1995 ; 1–2.</Citation></Reference><Reference><Citation>Hurst M, Faulds D. Lopinavir. Drugs 2000; 60 : 1371–9; discussion 80–1.</Citation></Reference><Reference><Citation>Capeau J, Caron M, Vigouroux C, et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l’infection par le VIH. Med Sci (Paris) 2006 ; 22 : 531–536.</Citation></Reference><Reference><Citation>Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000 ; 356 : 1423–1430.</Citation></Reference><Reference><Citation>Ravaud C, Pare M, Azoulay S, et al. Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors. Sci Rep 2017 ; 7 : 2986.</Citation></Reference><Reference><Citation>Ravaud C, Paré M, Yao X, et al. Resveratrol and HIV-protease inhibitors control UCP1 expression through opposite effects on p38 MAPK phosphorylation in human adipocytes. J Cell Physiol 2019 ; 235 : 1184–1196.</Citation></Reference><Reference><Citation>Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005 ; 280 : 2238–2243.</Citation></Reference><Reference><Citation>Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Bioph Res Co 2009 ; 386 : 96–100.</Citation></Reference><Reference><Citation>Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014 ; 281 : 4085–4096.</Citation></Reference><Reference><Citation>Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science 2020; 368 : 409–12.</Citation></Reference><Reference><Citation>Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CL<sup>pro</sup>) structure: basis for design of anti-SARS drugs. Science 2003 ; 300 : 1763–1767.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 : 1787–99.</Citation></Reference><Reference><Citation>Lapatto R, Blundell T, Hemmings A, et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989 ; 342 : 299–302.</Citation></Reference><Reference><Citation>Juckel D, Dubuisson J, Belouzard S. Les coronavirus, ennemis incertains. Med Sci (Paris) 2020, 36: 633–41.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Nice</li></settlement></list><tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Ladoux, Annie" sort="Ladoux, Annie" uniqKey="Ladoux A" first="Annie" last="Ladoux">Annie Ladoux</name></region><name sortKey="Azoulay, Stephane" sort="Azoulay, Stephane" uniqKey="Azoulay S" first="Stéphane" last="Azoulay">Stéphane Azoulay</name><name sortKey="Dani, Christian" sort="Dani, Christian" uniqKey="Dani C" first="Christian" last="Dani">Christian Dani</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32558640
|texte= [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32558640" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |